Renal Disease
Lamivudine-resistant hepatitis B virus thrives in kidney graft recipients
Published in Blood Weekly, August 26th, 2004
"The natural history of lamivudine-resistant hepatitis B virus (HBV) infection in renal transplant recipients (RTx) is unclear, despite its increasing incidence. Twenty-nine HBsAg-positive RTx with rising HBV DNA received lamivudine therapy. The course of lamivudine-resistant HBV infection was studied prospectively," scientists in the Peoples Republic of China report.
"During 68.7±12.5 months of follow-up, 14 (48.3%) patients developed lamivudine resistance, at 10-35 months (mean 16.9±7.0). All showed mutant sequences at codons 552 and 528 of the YMDD motif,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2004-08-26)
More Articles from Blood Weekly
- Blood Banking
Hemolysate-filled PEI/PU microcapsules potential red blood cell substitutes - Extracorporeal Detoxification
Large-bore catheter complications characterized - Hematology
Oxygen binding of hemoglobin conjugated to carboxylate dextran reported - Herpesvirus
HHV-8-specific antibodies detected in HSCT recipients by peptide-based EIA - Kaposi Sarcoma-Associated Herpesvirus
KSHV infection can predispose cells to malignant transformation - Allergy & Immunology
IL-9 increases cytokine expression in activated mast cells - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
